Consider QUTENZA as your first add-on treatment for patients with PHN

PHN: postherpetic neuralgia.
Not an actual patient.

Yellow Angle Shape

Study 1 and 2 Primary Endpoint: QUTENZA resulted in a significantly greater reduction in mean NPRS scores from baseline to Week 8 compared to control1

With QUTENZA,

QUTENZA demonstrated pain reduction—starting as early as Week 11

Pain scores decreased about 30% and sustained through Week 121

PHN Study 12: Percent Change in Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Scores by Week

PHN Study 23: Percent Change in Average Pain for the Past 24 Hours NPRS Scores by Week

Demonstrated pain reduction—starting as early as Week 1
Pain scores decreased about 30% and sustained through Week 12

Mean percent changes in NPRS scores from baseline to Week 8 were -29% for QUTENZA vs -18% for control (P=0.001).

Mean percent changes in NPRS scores from baseline to Week 8 were -33% for QUTENZA vs -26% for control (P=0.001).

Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 402 PHN patients.1

Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients.1

In both studies, some patients experienced significant pain reduction through 12 weeks.1

Note: The control used in these studies appeared identical to QUTENZA and contained a low (0.04%) concentration of capsaicin to retain blinding.1

Study 1 and 2 Primary Endpoint: QUTENZA resulted in a significantly greater reduction in mean NPRS scores from baseline to Week 8 compared to control1

QUTENZA demonstrated pain reduction—starting as early as Week 11

PHN Study 12: Percent Change in Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Scores by Week

Demonstrated pain reduction—starting as early as Week 1

Mean percent changes in NPRS scores from baseline to Week 8 were -29% for QUTENZA vs -18% for control (P=0.001).

Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 402 PHN patients.1

With QUTENZA,

Pain scores decreased about 30% and sustained through Week 121

PHN Study 23: Percent Change in Average Pain for the Past 24 Hours NPRS Scores by Week

Pain scores decreased about 30% and sustained through Week 12

Mean percent changes in NPRS scores from baseline to Week 8 were -33% for QUTENZA vs -26% for control (P=0.001).

Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients.1

In both studies, some patients experienced significant pain reduction through 12 weeks.1

Note: The control used in these studies appeared identical to QUTENZA and contained a low (0.04%) concentration of capsaicin to retain blinding.1

In the QUTENZA arm of Study 1 and Study 2,

In the QUTENZA arm of Study 2,

Secondary Endpoint: Over 40% of patients achieved ≥30% reduction in pain scores1

Secondary Endpoint: 30% of patients achieved ≥50% reduction in pain scores1

Percentage of patients achieving ≥30% reduction in mean NPRS scores2,3
(Baseline to Weeks 2-12; P=nominal)

Percentage of patients achieving ≥50% reduction in mean NPRS score3
(Baseline to Weeks 2-12; P=nominal)

Over 40% of patients achieved ≥30% reduction in pain scores
30% of patients achieved ≥50%reduction in pain scores

*

Study 1: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 402 PHN patients (N=205 QUTENZA, N=197 Control).1,2

Study 2: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients (N=212 QUTENZA, N=204 Control).1,3

Study 2: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients.1,3

In the QUTENZA arm of Study 1 and Study 2,

Secondary Endpoint: Over 40% of patients achieved ≥30% reduction in pain scores1

Percentage of patients achieving ≥30% reduction in mean NPRS scores2,3
(Baseline to Weeks 2-12; P=nominal)

Over 40% of patients achieved ≥30% reduction in pain scores

*

Study 1: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 402 PHN patients (N=205 QUTENZA, N=197 Control).1,2

Study 2: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients (N=212 QUTENZA, N=204 Control).1,3

In the QUTENZA arm of Study 2,

Secondary Endpoint: 30% of patients achieved ≥50% reduction in pain scores1

Percentage of patients achieving ≥50% reduction in mean NPRS score3
(Baseline to Weeks 2-12; P=nominal)

30% of patients achieved ≥50%reduction in pain scores

Study 2: Results from a 12-week, double-blind, randomized, dose-controlled, multicenter study of 416 PHN patients.1,3

See how QUTENZA works differently to target pain associated with PHN.

PHN MOA Video
Efficacy was demonstrated regardless of concomitant use of other medications

Approximately half of the patients in the studies were taking concomitant medications, including anticonvulsants, non-selective serotonin reuptake inhibitor (SSRI) antidepressants, or opioids, at study entry and were required to keep dosing stable throughout the duration of the study.2